首页> 美国卫生研究院文献>American Journal of Physiology - Lung Cellular and Molecular Physiology >Translational Research in Acute Lung Injury and Pulmonary Fibrosis: Effect of a chemical chaperone tauroursodeoxycholic acid on HDM-induced allergic airway disease
【2h】

Translational Research in Acute Lung Injury and Pulmonary Fibrosis: Effect of a chemical chaperone tauroursodeoxycholic acid on HDM-induced allergic airway disease

机译:急性肺损伤和肺纤维化的转化研究:化学伴侣牛磺去氧胆酸对HDM引起的过敏性气道疾病的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Endoplasmic reticulum (ER) stress-induced unfolded protein response plays a critical role in inflammatory diseases, including allergic airway disease. However, the benefits of inhibiting ER stress in the treatment of allergic airway disease are not well known. Herein, we tested the therapeutic potential of a chemical chaperone, tauroursodeoxycholic acid (TUDCA), in combating allergic asthma, using a mouse model of house dust mite (HDM)-induced allergic airway disease. TUDCA was administered during the HDM-challenge phase (preventive regimen), after the HDM-challenge phase (therapeutic regimen), or therapeutically during a subsequent HDM rechallenge (rechallenge regimen). In the preventive regimen, TUDCA significantly decreased HDM-induced inflammation, markers of ER stress, airway hyperresponsiveness (AHR), and fibrosis. Similarly, in the therapeutic regimen, TUDCA administration efficiently decreased HDM-induced airway inflammation, mucus metaplasia, ER stress markers, and AHR, but not airway remodeling. Interestingly, TUDCA administered therapeutically in the HDM rechallenge regimen markedly attenuated HDM-induced airway inflammation, mucus metaplasia, ER stress markers, methacholine-induced AHR, and airway fibrotic remodeling. These results indicate that the inhibition of ER stress in the lungs through the administration of chemical chaperones could be a valuable strategy in the treatment of allergic airway diseases.
机译:内质网(ER)应激诱导的未折叠蛋白应答在包括过敏性气道疾病在内的炎性疾病中起关键作用。然而,在过敏性气道疾病的治疗中抑制ER应激的益处尚不清楚。在本文中,我们使用屋尘螨(HDM)诱发的过敏性气道疾病小鼠模型,测试了化学分子伴侣tauroursodeoxycholic acid(TUDCA)在对抗过敏性哮喘中的治疗潜力。在HDM挑战阶段(预防方案),HDM挑战阶段之后(治疗方案)或随后的HDM再挑战(重新挑战方案)进行治疗时,给予TUDCA。在预防方案中,TUDCA显着降低了HDM诱导的炎症,ER应激指标,气道高反应性(AHR)和纤维化。同样,在治疗方案中,TUDCA的使用可有效减少HDM诱导的气道炎症,粘液化生,ER应激指标和AHR,但不能减轻气道重塑。有趣的是,在HDM再挑战方案中进行治疗性给药的TUDCA显着减轻了HDM诱导的气道炎症,粘液化生,ER应激标记,乙酰甲胆碱诱导的AHR和气道纤维化重塑。这些结果表明,通过施用化学分子伴侣抑制肺内质网应激可能是治疗过敏性气道疾病的有价值的策略。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号